Payment overview · 2025
General Payments
$632.28
26 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher J Quinn, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRANGER, IN · NPI 1073503512
Verified facts
What the public records show
CMS Open Payments records show Christopher J Quinn, MD received $632.28 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 62.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Paxlovid, Rexulti, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1201 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $391.97 | 62.0% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.82 | 11.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.54 | 6.9% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $43.44 | 6.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.06 | 4.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.23 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.37 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $613.43 | 25 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $375.82 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $71.82 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 18 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1201 | 88 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2037 | 253 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1911 | 301 |
| Amlodipine Besylate | Amlodipine Besylate | 1556 | 221 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1332 | 151 |
| Eliquis | Apixaban | 1201 | 88 |
| Potassium Chloride | Potassium Chloride | 1130 | 112 |
| Gabapentin | Gabapentin | 832 | 86 |
| Furosemide | Furosemide | 805 | 132 |
| Metoprolol Tartrate | Metoprolol Tartrate | 739 | 92 |
| Lisinopril | Lisinopril | 700 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 683 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 676 | 94 |
| Escitalopram Oxalate | Escitalopram Oxalate | 652 | 90 |
| Losartan Potassium | Losartan Potassium | 650 | 106 |
| Donepezil Hcl | Donepezil Hcl | 641 | 58 |
| Sertraline Hcl | Sertraline Hcl | 630 | 74 |
| Famotidine | Famotidine | 522 | 44 |
| Metformin Hcl | Metformin Hcl | 511 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 472 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 431 | 38 |
| Trazodone Hcl | Trazodone Hcl | 348 | 48 |
| Memantine Hcl | Memantine Hcl | 321 | 39 |
| Carvedilol | Carvedilol | 316 | 33 |
| Warfarin Sodium | Warfarin Sodium | 316 | 11 |
| Omeprazole | Omeprazole | 277 | 52 |
| Ezetimibe | Ezetimibe | 266 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 66 |
| Levetiracetam | Levetiracetam | 256 | 11 |
| Simvastatin | Simvastatin | 232 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 198 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 51 |
| Baclofen | Baclofen | 192 | 17 |
| Mirtazapine | Mirtazapine | 189 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 30 |
| Metformin Hcl Er | Metformin Hcl | 175 | 36 |
| Bupropion Xl | Bupropion Hcl | 170 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 168 | 11 |
| Montelukast Sodium | Montelukast Sodium | 168 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 167 | 17 |
| Buspirone Hcl | Buspirone Hcl | 154 | 14 |
| Xarelto | Rivaroxaban | 152 | 12 |
| Torsemide | Torsemide | 147 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 33 |
| Glimepiride | Glimepiride | 146 | 19 |
| Prednisone | Prednisone | 145 | 34 |
| Finasteride | Finasteride | 143 | 18 |
| Midodrine Hcl | Midodrine Hcl | 139 | 20 |
| Allopurinol | Allopurinol | 136 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 132 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 131 | 17 |
| Sotalol | Sotalol Hcl | 130 | suppressed |
| Topiramate | Topiramate | 129 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 127 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 126 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 18 |
| Tradjenta | Linagliptin | 115 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 112 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 112 | 19 |
| Meloxicam | Meloxicam | 111 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 34 |
| Cephalexin | Cephalexin | 103 | 56 |
| Januvia | Sitagliptin Phosphate | 103 | 13 |
| Spironolactone | Spironolactone | 102 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 26 |
| Scopolamine | Scopolamine | 97 | 11 |
| Labetalol Hcl | Labetalol Hcl | 93 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 91 | 24 |
| Jardiance | Empagliflozin | 91 | 20 |
| Chlorthalidone | Chlorthalidone | 90 | suppressed |
| Alprazolam | Alprazolam | 89 | 28 |
| Gemtesa | Vibegron | 89 | suppressed |
| Clonazepam | Clonazepam | 88 | suppressed |
| Azithromycin | Azithromycin | 86 | 68 |
| Dofetilide | Dofetilide | 84 | suppressed |
| Insulin Lispro | Insulin Lispro | 84 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 42 |
| Bumetanide | Bumetanide | 82 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 81 | suppressed |
| Nystatin | Nystatin | 81 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 17 |
| Creon | Lipase/Protease/Amylase | 79 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 79 | suppressed |
| Glipizide | Glipizide | 78 | 17 |
| Atenolol | Atenolol | 77 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 74 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 39 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 73 | suppressed |
| Valsartan | Valsartan | 73 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 24 |
| Farxiga | Dapagliflozin Propanediol | 71 | suppressed |
| Trulicity | Dulaglutide | 71 | suppressed |
| Lansoprazole | Lansoprazole | 69 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 65 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 65 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Folic Acid | Folic Acid | 62 | suppressed |
| Myrbetriq | Mirabegron | 62 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 13 |
| Sucralfate | Sucralfate | 62 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 62 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 42 |
| Amoxicillin | Amoxicillin | 59 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 29 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 59 | suppressed |
| Latanoprost | Latanoprost | 59 | 11 |
| Dilantin | Phenytoin Sodium Extended | 58 | suppressed |
| Rexulti | Brexpiprazole | 58 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Methocarbamol | Methocarbamol | 54 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | suppressed |
| Zonisamide | Zonisamide | 53 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 52 | 15 |
| Brilinta | Ticagrelor | 52 | suppressed |
| Carbamazepine | Carbamazepine | 52 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 52 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 51 | suppressed |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 50 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 49 | suppressed |
| Ozempic | Semaglutide | 49 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 14 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Irbesartan | Irbesartan | 45 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Loperamide | Loperamide Hcl | 43 | 23 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 42 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | 14 |
| Entacapone | Entacapone | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Ondansetron Odt | Ondansetron | 35 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Repaglinide | Repaglinide | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 22 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 20 |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 23 | suppressed |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Diltiazem 12hr Er | Diltiazem Hcl | 22 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Fluconazole | Fluconazole | 20 | 15 |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | 13 |
| Metronidazole | Metronidazole | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Mupirocin | Mupirocin | 17 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Tobramycin | Tobramycin | 17 | 17 |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Trexall | Methotrexate Sodium | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Glatopa | Glatiramer Acetate | 13 | suppressed |
| Glucagen | Glucagon | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 13 |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $632.28 · 26 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, INSPIRE, JARDIANCE, NURTEC ODT, PAXLOVID, PREVNAR 20, REXULTI, SHINGRIX, UBRELVY, VRAYLAR, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error